Effective April 15, 2017, CVS Caremark® will add buprenorphine/opioid to the list of DUR edits for CareSource Medicaid and Marketplace. Buprenorphine sublingual (SL) tablets and buprenorphine/naloxone SL film/tablets are indicated for the treatment of opioid dependency. Use of these products should be part of a complete treatment plan, which includes counseling and psychosocial support. Concomitant use of these products with opiates may lead to serious adverse events.

*Please see attached PDF for more information.